Wedbush initiated coverage on Rani Therapeutics with a new price target
$RANI
Biotechnology: Pharmaceutical Preparations
Health Care
Wedbush initiated coverage of Rani Therapeutics with a rating of Outperform and set a new price target of $28.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/2/2024 | $17.00 | Outperform | Oppenheimer |
| 6/14/2024 | $15.00 | Buy | Maxim Group |
| 6/13/2024 | $10.00 | Buy | Rodman & Renshaw |
| 4/17/2023 | $24.00 | Buy | BTIG Research |
| 10/11/2022 | $15.00 | Buy | UBS |
| 7/27/2022 | $22.00 | Buy | H.C. Wainwright |
| 6/13/2022 | $28.00 | Outperform | Wedbush |
| 8/25/2021 | $24.00 | Buy | BTIG |
DEF 14C - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
EFFECT - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
424B5 - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
Oppenheimer initiated coverage of Rani Therapeutics with a rating of Outperform and set a new price target of $17.00
Maxim Group initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $15.00
Rodman & Renshaw initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $10.00
SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company's management team will participate in the upcoming Evercore Healthcare Conference. Details below: 8th Annual Evercore Healthcare ConferenceDate: Wednesday, December 3, 2025 at 8:45 am E.T.Location: Coral Gables, FLPresenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai SanfordFormat: Fireside Chat and 1x1 Meetings Interested parties can access the live webcast for this conference from the Investor Relations
– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Anomaly, Special Situations Funds, and Invus – – Appointed Abraham Bassan and Vasudev Bailey, Ph.D. to the Board of Directors – – Cash runway expected to extend into 2028 – SAN JOSE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the third
SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule, the company's oral delivery platform, at ObesityWeek® 2025 taking place both virtually and in-person on November 4-7, 2025 in Atlanta, Georgia. Details of the presentation are as follows: Abstract Title: Oral Semaglutide (RT-116) in Dogs is Bioequivalent to SC Injections and Elicits Similar Weight LossSession Type: Poster SessionPoster Number: 647Location: Georgia World Congress Center,
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
3 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Anomaly, Special Situations Funds, and Invus – – Appointed Abraham Bassan and Vasudev Bailey, Ph.D. to the Board of Directors – – Cash runway expected to extend into 2028 – SAN JOSE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the third
SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Abraham ("Abe") Bassan and Vasudev Bailey, Ph.D., to its Board of Directors. In conjunction with the new appointments, Andrew Farquharson and Maulik Nanavaty have stepped down from the Board of Directors. "We are thrilled to welcome Abe and Vasudev to our Board of Directors as we enter an exciting new era for Rani, highlighted by both our clinical-stage pipeline and expansion opportunities into high-value therapeutics from our rece
- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of Presidential Poster Competition in its category for exceptional scientific work on RT-102 - Presentation of late-breaking abstract on oral delivery of GLP-1 agonist at American Diabetes Association's Scientific Sessions - Plan to initiate Phase 2 study for RT-102 and Phase 1 study for RT-111 in 2H of 2023 SAN JOSE, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings,
- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule - - Preclinical data of four incretin-based molecules underscores the RaniPill® platform's potential to facilitate the oral delivery of a diverse array of obesity treatments - - Phase 1 study for RT-114 for the treatment of obesity, expected to initiate in mid-2025 - - Conference call today at 4:30 p.m. ET / 1:30 p.m. PT - SAN JOSE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeut
SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2024 and provide a business update on Monday, March 31, 2025 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 31, 2025. Individuals interested in listenin
~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani and ProGen to share responsibilities for the development and commercialization of RT-114, including a 50/50 cost and revenue share arrangement ~ ~ Rani to host conference call today at 8:00 a.m. ET/5:00 a.m. PT ~ SAN JOSE, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani")(NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and
SC 13G - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)
SC 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)
SC 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)